Humacyte, Inc. (NASDAQ:HUMA) Receives $13.00 Consensus Target Price from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has been assigned an average recommendation of “Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $13.43.

HUMA has been the topic of several research analyst reports. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Friday. Benchmark reiterated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th.

Humacyte Stock Up 34.1 %

HUMA opened at $4.64 on Thursday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10. Humacyte has a one year low of $2.48 and a one year high of $9.97. The business’s 50-day simple moving average is $4.83 and its 200-day simple moving average is $5.84. The stock has a market capitalization of $583.99 million, a P/E ratio of -3.46 and a beta of 1.38.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Laura E. Niklason sold 261,369 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,500,000 shares of company stock valued at $6,606,799 over the last ninety days. Insiders own 11.20% of the company’s stock.

Hedge Funds Weigh In On Humacyte

A number of hedge funds have recently made changes to their positions in the business. nVerses Capital LLC acquired a new stake in shares of Humacyte during the 2nd quarter worth about $28,000. Concurrent Investment Advisors LLC bought a new stake in shares of Humacyte in the 3rd quarter valued at $75,000. Principal Financial Group Inc. bought a new stake in Humacyte during the 2nd quarter worth approximately $83,000. FORA Capital LLC bought a new position in Humacyte during the 3rd quarter worth about $96,000. Finally, Insigneo Advisory Services LLC acquired a new stake in shares of Humacyte in the third quarter valued at about $109,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.